Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Treatment-related adverse events reported in ≥ 10% of patients (n = 27)

From: Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation

Drug-related AE All grades
N (%)
Grade 3
N (%)
Fatigue 13 (48%) 4 (15%)
Rash 12 (44%) 7 (26%)
Vomiting 8 (30%) 0
Nausea 7 (26%) 0
Diarrhea 7 (16%) 0
Pain 5 (19%) 1 (4%)
AST increased 4 (15%) 2 (7%)
Hyperglycemia 4 (15%) 1 (4%)
Pruritus 4 (15%) 1 (4%)
Anorexia 4 (15%) 0
Mucositis 4 (15%) 0
Insomnia 3 (11%) 0
Anemia 3 (11%) 0
Sore throat 3 (11%) 0
Dysgeusia 3 (11%) 0
Constipation 3 (11%) 0